KRAS and non-small cell lung carcinoma: According to the KRYSTAL-1 phase 1/2 trial results, in patients with advanced NSCLC G12C KRAS mutant tumors previously treated with chemotherapy and anti-PDL1 therapy, Adagrasib yielded a 96% disease control rate with a 45% objective response rate [16].